Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

MSE PRO Thiomorpholin-3-one, ≥99.0% Purity– MSE Supplies LLC

Free Shipping on MSE PRO Online Orders of $500 or More! U.S. Orders Only * Offer Excludes Hazmat Shipments *

Menu
Cart

This product has been added to the cart.

MSE PRO Thiomorpholin-3-one, ≥99.0% Purity - MSE Supplies LLC

MSE PRO Thiomorpholin-3-one, ≥99.0% Purity

SKU: CM1381

  • £13000
  • Save £1400

MSE PRO™ Thiomorpholin-3-one, ≥99.0% Purity

MSE PRO™ Thiomorpholin-3-one serves as a versatile building block in organic synthesis, offering a wide range of possibilities for creating novel compounds with varied chemical properties. It contains a thiomorpholine ring with a carbonyl group (C=O) at the third position, conferring unique reactivity and potential pharmacological activity. Thiomorpholin-3-one derivatives have drawn interest in pharmaceutical research due to their potential as drug candidates. Researchers explore its pharmacological properties, including antimicrobial, antiviral, and anticancer activities.

MSE Supplies offers various N-heterocyclic drug small molecules and other chemical reagents. Please contact us for bulk orders.

Technical Specifications:

CAS No.
20196-21-8
Chemical name Thiomorpholin-3-one
Molecular formula C4H7NOS     
Synonym(s)

· 3-Thiomorpholinone

· 3-Oxothiomorpholine
Pack size

5 g (CM1381)
Molecular weight 117.17 g/mol
Purity 99.67% (GC)
Melting point     87-89 °C
Boiling point  185 °C
Density 1.189±0.06 g/mL (Predicted)
pKa 12.36±0.20 (Predicted)
Appearance Light yellow to yellow solid
Storage 
 Store at room temperature


References:

[1] Swain, S. S., Pati, S., & Hussain, T. (2022). Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation. European Journal of Medicinal Chemistry, 232, 114173.

[2] Chamariya, R., & Suvarna, V. (2022). Role of KSP inhibitors as anti-cancer therapeutics: an update. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 22(14), 2517-2538.